First Word

COVID-19 UPDATE: FDA issues EUA for Eli Lilly's Olumiant (baricitinib) for treatment of COVID-19. Mere days after UK study. That was fast and VERY POSITIVE. Mortality shown down 71%

Click HERE to access the FSInsight COVID-19 Daily Chartbook.

STRATEGY: Market is bi-furcating... Epicenter surges on healthcare progress
We got some very good news after the close yesterday regarding treatments for COVID-19.  The FDA issued an EUA (Emergency Use Authorization) for Olumiant (baricitinib), the rheumatoid arthritis drug, to be used for the treatment of COVID-19, alongside Remdesivir.  We had written about Olumiant this past Sunday, as a Swedish/UK study showed it reduced mortality by 71%.

The video in this report is only accessible to members

Source: Bloomberg

- Wow.  The FDA moved lightning fast
- Olumiant was shown to reduce mortality by 71% and was effective for older patients

The video in this report is only accessible to members
Source: FDAIn just the past few weeks, we have witnessed advances in the treatment and prevention of COVID-19.  While we are not yet seeing this in reduced cases or mortality, these collectively should slow the scourge of COVID-19 and eventually stop it in its tracks (vaccine):Prevention- Vaccine candidated by Moderna and Pfizer- Vitamin D (UK govt proposal)Treatment/Cure- Olumiant- steroids- antibody cocktailsSo while COVID-19 remains a deadly disease, the medical progress is bringing considerable hope.Index is treading water, as "Epicenter" stocks take the lead... properly responding to improved healthcare outlookAs for...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

More from the author

Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.

Already have an account? Sign In

Want to receive Regular Market Updates to your Inbox?

I am your default error :)